A2B5-reactive gangliosides (A2B5)

A2B5-reactive gangliosides are a specific subset of c-series glycosphingolipids, notably GT3 and its O-acetylated derivatives, which are recognized by the A2B5 monoclonal antibody (PubMed: 15173168). These antigens are prominently expressed on the surface of glioma stem-like cells (GSCs), a subpopulation of cells within glioblastomas that drive tumor growth, invasion, and resistance to standard therapies (PubMed: 19117938). In normal physiology, A2B5 serves as a marker for oligodendrocyte precursor cells (OPCs) and other neural progenitors, playing a role in cell-cell interactions and signaling during neurodevelopment (PubMed: 22499518). Because of their high prevalence on the surface of aggressive tumor-initiating cells, these gangliosides have become significant targets for novel immunotherapies, including chimeric antigen receptor (CAR) T-cell therapy and antibody-drug conjugates (PubMed: 33009411). Targeting A2B5-positive cells aims to eliminate the reservoir of cells responsible for tumor recurrence in glioblastoma patients. However, a major therapeutic challenge is the potential for off-tumor, on-target toxicity, as the antigens are also present on healthy glial precursors in the central nervous system. Current research focuses on optimizing the therapeutic window to selectively target malignant cells while sparing normal neural tissue.

Other names

GT3 gangliosideO-acetylated GT3c-series gangliosidesA2B5 antigensA2B5-positive cell markers

Direct binding to cell-surface gangliosides to induce immune-mediated cell lysis via CAR-T activation or antibody-dependent cellular cytotoxicity (ADCC), and potential disruption of stemness-related signaling pathways.